BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 38082368)

  • 1. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
    Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
    J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD-A Pilot Study.
    Zyśk B; Ostrowska L; Smarkusz-Zarzecka J; Orywal K; Mroczko B; Cwalina U
    Nutrients; 2024 May; 16(9):. PubMed ID: 38732626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
    Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
    Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel gene signature to diagnose MASLD in metabolically unhealthy obese individuals.
    Meroni M; Chiappori F; Paolini E; Longo M; De Caro E; Mosca E; Chiodi A; Merelli I; Badiali S; Maggioni M; Mezzelani A; Valenti L; Ludovica Fracanzani A; Dongiovanni P
    Biochem Pharmacol; 2023 Dec; 218():115925. PubMed ID: 37981173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of adipose tissue and subsequent liver tissue hypoxia in obesity and early stage metabolic dysfunction associated steatotic liver disease.
    Van Eyck A; Kwanten WJ; Peleman C; Makhout S; Van Laere S; Van De Maele K; Van Hoorenbeeck K; De Man J; De Winter BY; Francque S; Verhulst SL
    Int J Obes (Lond); 2024 Apr; 48(4):512-522. PubMed ID: 38142264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose.
    Tan BK; Adya R; Farhatullah S; Lewandowski KC; O'Hare P; Lehnert H; Randeva HS
    Diabetes; 2008 Apr; 57(4):801-8. PubMed ID: 18174521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in metabolic dysfunction-associated steatotic liver disease.
    Sarabhai T; Kahl S; Gancheva S; Mastrototaro L; Dewidar B; Pesta D; Ratter-Rieck JM; Bobrov P; Jeruschke K; Esposito I; Schlensak M; Roden M
    Metabolism; 2024 Feb; 151():155762. PubMed ID: 38122893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFα is a key trigger of inflammation in diet-induced non-obese MASLD in mice.
    Burger K; Jung F; Baumann A; Brandt A; Staltner R; Sánchez V; Bergheim I
    Redox Biol; 2023 Oct; 66():102870. PubMed ID: 37683301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
    Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
    Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma.
    Syamprasad NP; Jain S; Rajdev B; Panda SR; Kumar GJ; Shaik KM; Shantanu PA; Challa VS; Jorvekar SB; Borkar RM; Vaidya JR; Tripathi DM; Naidu VGM
    JHEP Rep; 2024 Feb; 6(2):100974. PubMed ID: 38283757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.